US 12,070,489 B2
Method of treating cancer with a cancer therapy in combination with another therapeutic agent
Yuval Shaked, Binyamina (IL); Ziv Raviv, Haifa (IL); and Dror Yeger, Zichron Yaakov (IL)
Assigned to Rappaport Family Institute for Research In the Medical Sciences, Haifa (IL)
Filed by Rappaport Family Institute for Research in the Medical Sciences, Haifa (IL)
Filed on Dec. 12, 2019, as Appl. No. 16/712,800.
Application 16/712,800 is a continuation in part of application No. 16/218,177, filed on Dec. 12, 2018.
Prior Publication US 2020/0190183 A1, Jun. 18, 2020
Int. Cl. A61K 38/20 (2006.01); A61K 38/17 (2006.01); A61P 35/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); A61K 45/06 (2006.01); A61P 31/00 (2006.01)
CPC A61K 38/2046 (2013.01) [A61K 38/177 (2013.01); A61P 35/00 (2018.01); C07K 16/248 (2013.01); C07K 16/2866 (2013.01); G01N 33/574 (2013.01); A61K 45/06 (2013.01); A61P 31/00 (2018.01)] 14 Claims
 
1. A method of treating a colon cancer patient with radiotherapy, the method comprising the steps of:
(i) calculating a fold change in Interleukin 7 (IL-7) protein expression produced by said colon cancer patient in response to treatment with said radiotherapy in blood samples obtained from said cancer patient before a first treatment with said radiotherapy and after said first treatment with said radiotherapy, wherein said blood sample is selected from the group consisting of blood plasma, whole blood, blood serum and peripheral blood mononuclear cells; wherein an increase in protein expression from before said first treatment to after said first treatment of IL-7 indicates a colon cancer patient with a non-favorable response to said treatment with said radiotherapy; and
(ii) treating said patient with a non-favorable response with an antibody that binds to IL-7 receptor (IL-7R) and blocks its activity, in combination with a second treatment with said radiotherapy.